Beta Bionics, Inc. (BBNX)

Market Cap	454.30M
Revenue (ttm)	65.12M
Net Income (ttm)	-54.76M
Shares Out	43.35M
EPS (ttm)	-8.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,711
Open	10.40
Previous Close	10.46
Day's Range	10.03 - 10.61
52-Week Range	8.89 - 24.50
Beta	n/a
Analysts	Strong Buy
Price Target	26.67 (+154.49%)
Earnings Date	May 6, 2025

About BBNX

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combine...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 2025
• Employees: 294
• Stock Exchange: NASDAQ
• Ticker Symbol: BBNX
• Website: https://www.betabionics.com

Financial Performance

In 2024, Beta Bionics's revenue was $65.12 million, an increase of 442.93% compared to the previous year's $12.00 million. Losses were -$54.76 million, 24.2% more than in 2023.

Financial numbers in USD

Analyst Forecast

According to 6 analysts, the average rating for BBNX stock is "Strong Buy." The 12-month stock price forecast is $26.67, which is an increase of 154.49% from the latest price.

Price Target

$26.67

(154.49% upside)

Analyst Consensus: Strong Buy